文献速递肺外科心外重症与机械循环支持

肺纤维化肺移植术中体外循环支持的危险因素

Intraoperative Extracorporeal Circulatory Support in Lung Transplantation for Pulmonary Fibrosis.
PubMed 文献 · Ann Thorac Surg · 2020-09-03

该回顾性研究纳入2010年1月至2018年5月因肺纤维化行肺移植的患者,分析术中需体外膜氧合(ECMO)支持的危险因素。结果显示术前肺动脉高压、平均肺动脉压超过50 mm Hg及肺血管阻力超过9.4 Wood units是危险因素,而较大体表面积和高心输出量为保护因素;ECMO+组术后病程更复杂,但5年生存率无显著差异。

要点

  • 术前肺动脉高压使术中需ECMO支持的风险增加(OR 3.8)。
  • 平均肺动脉压>50 mm Hg和肺血管阻力>9.4 Wood units预测需ECMO。
  • ECMO+组术后并发症更多,但5年生存率无显著差异。

核心结论

  • 肺动脉高压伴肺血管阻力升高可预测肺纤维化肺移植患者术中需ECMO支持。
  • 尽管ECMO+组术后病程更复杂,但长期生存无显著差异。

研究设计与样本

  • 回顾性队列研究,纳入2010年1月至2018年5月单中心因肺纤维化行肺移植的患者。
  • 采用单因素逻辑回归分析识别危险因素。

主要发现

  • 术前肺动脉高压是术中需ECMO的危险因素(OR 3.8;95%CI 2.2-6.5;P<.01)。
  • 平均肺动脉压>50 mm Hg和肺血管阻力>9.4 Wood units预测需ECMO的概率为70%。
  • 较大体表面积(OR 0.2;95%CI 0.1-0.5;P<.01)和高心输出量(OR 0.7;95%CI 0.6-0.9;P<.01)为保护因素。
  • ECMO+组术后病程更复杂,但5年生存率无显著差异(70% vs 69%,P=.79)。

临床怎么用

  • 对肺纤维化肺移植患者,术前应评估肺动脉压力和肺血管阻力以预判术中ECMO需求。
  • 平均肺动脉压>50 mm Hg或肺血管阻力>9.4 Wood units时需警惕术中ECMO支持。

局限性

  • 回顾性单中心研究,样本量有限。
  • 仅采用单因素逻辑回归分析,未进行多因素校正。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous-arterial extracorporeal membrane oxygenation (ECMO) is an established technique for intraoperative cardiopulmonary support in patients undergoing lung transplantation. Patients with pulmonary fibrosis have a higher risk to require it. The aim of this study was to identify risk factors for the need of intraoperative ECMO use. METHODS: Records of patients undergoing lung transplantation for pulmonary fibrosis at our institution between January 2010 and May 2018 were retrospectively reviewed. Univariate logistic regression analysis was used for statistical identification of risk factors. RESULTS: There were 105 patients (34%) who required intraoperative ECMO support (ECMO+ group), and 203 (66%) did not (ECMO- group). Preoperative proof of pulmonary hypertension was identified as a risk factor for intraoperative ECMO support (odds ratio [OR], 3.8; 95% confidence interval [CI], 2.2-6.5; P < .01). Revealed mean pulmonary arterial pressure values exceeding 50 mm Hg and pulmonary vascular resistance values exceeding 9.4 Wood units were identified as risk factors for the need of intraoperative ECMO use with a prediction probability of 70%. Increased recipient body surface area (OR, 0.2; 95% CI, 0.1-0.5; P < .01) emerged as a protective factor against intraoperative ECMO (Hosmer-Lemeshow statistic, P = .71) as well as higher cardiac output (OR, 0.7; 95% CI, 0.6-0.9; P < .01). The postoperative course was more complicated in the ECMO+ group, whereas survival at 5 years did not differ among groups (70% vs 69%, P = .79). CONCLUSIONS: Pulmonary hypertension with elevated pulmonary vascular resistance values predicts the need of intraoperative ECMO in patients receiving lung transplantation for pulmonary fibrosis. Although the postoperative course was more complicated in the ECMO+ group, long-term survival did not differ significantly.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Salman J, Bernhard BA, Ius F, et al. Intraoperative Extracorporeal Circulatory Support in Lung Transplantation for Pulmonary Fibrosis. Ann Thorac Surg. 2020. PMID: 32890486. doi:10.1016/j.athoracsur.2020.06.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。